BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• Drug Development

  Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

  Incyte announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with prurigo nodularis.

  March 10, 2024

   · 

  7 min read
• Policy

  Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)

  Celltrion USA announced that the company has submitted a Biologics License Application for CT-P39, an interchangeable biosimilar candidate to XOLAIR® to the U.S. Food and Drug Administration.

  March 10, 2024

   · 

  5 min read